 MARLBOROUGH, Mass., Oct. 18, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. 